Scientific workshop “Beyond the first-line prenatal screening” in the city of Singapore

Singapore, 14 March 2024.

Gene Solutions is hosting a scientific workshop titled “Beyond the first-line prenatal screening” in the city of Singapore.

This event brings together top Obstetrics and Gynecology experts in the region to share about Severe Pregnancy Syndromes, the current statuses to prevent those syndromes, and the new clinical trends & evidence in early prediction of Pregnancy complications.

Key speakers includes Drs. Anna Belen I.Alensuela – Board Member of Philippine Obstetrical and Gynecology Society, Professor. Noroyono Wibowo – Head of Maternal Fetal Medicine of University of Indonesia, Associate Professor. Matthew Kemp – National University of Singapore, Dr. Giang Hoa – Institute of Medical Genetics HCMC & Gene Solutions Co-founder.

The workshop will also feature a new research topic: “Building and Evaluating an Early Prediction Model for Pregnancy Complications: Pre-eclampsia, Preterm Birth, and Gestational Diabetes in Non-Invasive Prenatal Testing (NIPT).” This topic represents the next-generation in NIPT applications. The research project is expected to involve collaboration among medical institutions, experts, and physicians from Southeast Asia.

We anticipate that in-depth presentations by international experts will provide valuable insights for healthcare professionals, allowing them to stay informed about cutting-edge developments in medical genetics.

Stay tuned for the latest updates on this program via the Gene Solutions fanpage or Linkedin Page!

Event Details:

Workshop Agenda:

Direct any questions regarding this event to Ms.Jean Huang, Senior Brand Manager Singapore & Malaysia, [email protected]

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More